Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole
Version of Record online: 16 SEP 2013
© 2013 John Wiley & Sons Ltd
Alimentary Pharmacology & Therapeutics
Volume 38, Issue 9, pages 1129–1137, November 2013
How to Cite
Sahara, S., Sugimoto, M., Uotani, T., Ichikawa, H., Yamade, M., Iwaizumi, M., Yamada, T., Osawa, S., Sugimoto, K., Umemura, K., Miyajima, H. and Furuta, T. (2013), Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Alimentary Pharmacology & Therapeutics, 38: 1129–1137. doi: 10.1111/apt.12492
- Issue online: 6 OCT 2013
- Version of Record online: 16 SEP 2013
- Manuscript Accepted: 28 AUG 2013
- Manuscript Revised: 22 AUG 2013
- Manuscript Revised: 24 JUL 2013
- Manuscript Received: 11 JUL 2013
- Ministry of Education, Culture, Sports, Science and Technology of Japan. Grant Numbers: 23590912, 23590913
- Japan Research Foundation for Clinical Pharmacology
Twice-daily dosing of proton pump inhibitors (PPIs) is used to treat Helicobacter pylori or acid-related diseases, such as gastro-oesophageal reflux disease (GERD) refractory to standard dose of a PPI. Genetic polymorphisms of CYP2C19 are involved to different extents in the metabolism of four kinds of PPIs (omeprazole, lansoprazole, rabeprazole and esomeprazole) available in Japan.
To compare acid-inhibitory effects of the four PPIs dosed twice daily in relation to CYP2C19 genotype.
We performed 24-h pH monitoring studies on Day 7 of PPI treatment for 40 Japanese H. pylori-negative volunteers [15 CYP2C19 rapid metabolisers (RMs), 15 intermediate metabolisers (IMs) and 10 poor metabolisers (PMs)] using a randomised four-way crossover design: omeprazole 20 mg, esomeprazole 20 mg, lansoprazole 30 mg and rabeprazole 10 mg twice daily.
Although median pH values with esomeprazole, omeprazole, lansoprazole and rabeprazole were 5.7 (3.5–7.2), 5.5 (2.4–7.2), 5.5 (3.7–7.3) and 5.2 (2.5–7.3), respectively (no statistically significant differences), CYP2C19 genotype-dependent differences were smaller for esomeprazole and rabeprazole compared with values for omeprazole and lansoprazole. In CYP2C19 RMs, the median pH with esomeprazole [5.4 (3.5–6.8)] was significantly higher than those with omeprazole [5.0 (2.4–5.9), P = 0.018], lansoprazole [4.7 (3.7-5.5), P = 0.017] or rabeprazole [4.8 (2.5–6.4), P = 0.002]. In IMs and PMs, the median pH was >5.0 independent of the PPI.
In intermediate and rapid metabolisers of CYP2C19, PPIs dosed twice daily could attain sufficient acid suppression, while in CYP2C19 RMs, esomeprazole 20 mg twice daily caused the strongest inhibition of the four PPIs. Therefore, esomeprazole may be effective in Japanese population when dosed twice daily.